Thalidomide-NH-PEG8-Ts is widely utilized in the field of targeted drug delivery and molecular biology research. Its structure, incorporating a polyethylene glycol (PEG) linker, enhances solubility and bioavailability, making it suitable for conjugating with various therapeutic agents. This compound is particularly valuable in the development of Proteolysis-Targeting Chimeras (PROTACs), where it facilitates the targeted degradation of specific proteins by recruiting E3 ubiquitin ligases. Additionally, its thalidomide moiety allows for the selective binding to cereblon, a key protein in the ubiquitin-proteasome system, enabling precise control over protein degradation pathways. This makes it a critical tool in cancer research, especially for targeting oncogenic proteins that are otherwise difficult to inhibit using traditional small-molecule drugs. Furthermore, its tosyl (Ts) group provides a reactive handle for further chemical modifications, allowing researchers to tailor the compound for specific applications in drug development and bioconjugation strategies.